Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Effect of time to relapse on OS in MCL following autoHCT

In patients with mantle cell lymphoma (MCL), outcomes are heterogeneous and the clinical significance of time of relapse following autologous hematopoietic cell transplantation (autoHCT) on overall survival (OS) is unknown. Peter Riedell, MD, University of Chicago Medicine, Chicago, IL, discusses the results of an investigation using the CIBMTR database to evaluate the effect of post-autoHCT time to relapse on OS over time. Dr Riedell discusses that in MCL, early relapse following autoHCT defines a high-risk group with inferior post-relapse OS. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

Disclosures

Peter A. Riedell, MD, reports research support/funding from Celgene/BMS, Kite Pharma, Inc./Gilead, MorphoSys, Calibr, Xencor, Tessa Therapeutics, and Novartis Pharmaceuticals Corporation; speaker’s bureau from Kite Pharma, Inc./Gilead and Bayer; consultancy on advisory boards from Verastem Oncology, Novartis Pharmaceuticals Corporation, Celgene/BMS, BeiGene, Karyopharm Therapeutics Inc., Takeda Pharmaceutical Company, and Bayer; honoraria from Novartis Pharmaceuticals Corporation.